European Medicines Agency: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
Tags: mobile edit mobile web edit
No edit summary
 
Line 30: Line 30:
{{EU-stub}}
{{EU-stub}}
{{medicine-stub}}
{{medicine-stub}}
{{No image}}
 
<gallery>
<gallery>
File:European_Medicines_Agency.svg|European Medicines Agency
File:European_Medicines_Agency.svg|European Medicines Agency
</gallery>
</gallery>

Latest revision as of 21:02, 16 March 2025

European Medicines Agency (EMA) is a European Union agency responsible for the evaluation and supervision of medicinal products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or EMEA.

History[edit]

The EMA was established in 1995 with the aim to harmonize the supervision of medicinal products in the EU. It replaced the Committee for Proprietary Medicinal Products and the Committee for Veterinary Medicinal Products, although both of these committees still exist within the EMA structure.

Function[edit]

The EMA is responsible for the scientific evaluation of applications for European marketing authorisation for medicinal products (a process known as the 'centralised procedure'). Once granted by the European Commission, a centralised (or 'Community') marketing authorisation is valid in all EU Member States, the European Economic Area-EFTA states (Iceland, Liechtenstein and Norway) and the UK.

Structure[edit]

The EMA operates as a decentralised scientific agency (as opposed to a regulatory authority) of the EU and is governed by a Management Board. The Board is composed of representatives of EU Member States, the European Commission, the European Parliament, patient organizations, and healthcare professionals.

Location[edit]

The EMA was originally located in London, United Kingdom, but moved to Amsterdam, the Netherlands, in March 2019 due to the UK's decision to leave the EU (Brexit).

Criticism and Controversy[edit]

The EMA has faced criticism over its handling of safety issues with approved drugs, with some critics claiming that the agency is too quick to approve drugs and too slow to withdraw them once problems become apparent.

See also[edit]

Stub icon
   This article is a  stub. You can help WikiMD by expanding it!




Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!